arrow
P

Padraig Warde

Princess Margaret Cancer Centre
H指数:78
被引数:2.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

MRI-guided HDR brachytherapy or integrated VMAT boost for tumour-targeted dose escalation in localised prostate cancer: long-term results of the TARGET study

MRI引导下的高剂量率近距离放射治疗或整合的VMAT推量放疗用于局部前列腺癌肿瘤靶向剂量递增:TARGET研究的长期结果

2026-11-060
PRE
Primary Retroperitoneal Lymph Node Dissection in Marker-Positive Clinical Stage II Nonseminomatous Germ Cell Tumors (vol 215, pg 326, 2026)

标志物阳性临床II期非精原细胞瘤生殖细胞肿瘤的初次腹膜后淋巴结清扫术(vol 215, pg 326, 2026)

2026-07-010
PRE
Postchemotherapy orchiectomy in metastatic testicular germ cell tumors: Pathologic findings and predictors of residual viable disease

术后化疗或睾丸切除术在转移性睾丸生殖细胞肿瘤中的病理发现和残余存活病灶的预测因子

2026-06-010
PRE
Moderate hypofractionated boost to the prostate with pelvic radiotherapy in high-risk prostate cancer (MOB-RT) − a phase 2 study: acute safety and quality of life outcomes

高危前列腺癌中盆腔放射治疗联合适当中分割剂量加强照射前列腺(MOB-RT)的Ⅱ期研究:急性安全性和生活质量结果

2026-05-230
PRE
Stereotactic body radiotherapy for renal tumors: a prospective phase 2 clinical trial

立体定向体部放射治疗肾肿瘤:一项前瞻性二期临床试验

2025-11-230
OAAI
Clinical Outcomes of Stage IIA/IIB Seminoma Treated With Radiation Therapy and Chemotherapy: Should Regional Therapy be Considered the Preferred Treatment Approach?

IIA/IIB 期精原细胞瘤采用放射治疗和化疗的临床疗效:是否应将区域治疗视为首选治疗方法?

2025-01-010
OAAI
Extended Results and Independent Validation of a Phase 2 Trial of Metastasis-Directed Therapy for Molecularly Defined Oligometastatic Prostate Cancer
2022-11-0114
PRE
Curative-intent Metastasis-directed Therapies for Molecularly- defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis

针对分子定义的低电流前列腺癌的治疗意图转移导向疗法: 一项测试寡转移假说的前瞻性II期试验

2021-09-0155
PREAI
Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen-receptor-targeted therapy for metastatic castration-resistant prostate cancer

癌症和衰老研究小组工具预测接受化疗或雄激素受体靶向治疗转移性去势抵抗性前列腺癌的老年男性毒性的能力

CANCER
IF5.1
2021-04-0225
OAAI